Mednax, Inc (NYSE:MD) insider John C. Pepia sold 3,000 shares of the business’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total transaction of $154,740.00. Following the completion of the sale, the insider now owns 35,569 shares of the company’s stock, valued at $1,834,649.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Mednax, Inc (MD) traded down $0.21 during trading hours on Tuesday, reaching $51.43. 806,200 shares of the company traded hands, compared to its average volume of 1,094,510. The firm has a market cap of $4,836.36, a PE ratio of 15.79, a P/E/G ratio of 1.66 and a beta of 0.40. Mednax, Inc has a 1 year low of $40.56 and a 1 year high of $72.13. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.62.

Mednax (NYSE:MD) last released its earnings results on Wednesday, November 1st. The company reported $0.87 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.87. The firm had revenue of $868.95 million during the quarter, compared to analysts’ expectations of $864.78 million. Mednax had a net margin of 7.76% and a return on equity of 10.80%. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the company earned $1.09 EPS. research analysts forecast that Mednax, Inc will post 3.1 EPS for the current fiscal year.

A number of analysts have recently weighed in on the stock. Jefferies Group restated a “hold” rating and issued a $44.00 price objective on shares of Mednax in a research note on Friday, November 3rd. KeyCorp upgraded shares of Mednax from a “sector weight” rating to an “overweight” rating and set a $51.00 price objective for the company in a research note on Sunday, September 17th. Citigroup reduced their price objective on shares of Mednax from $52.00 to $47.00 and set a “neutral” rating for the company in a research note on Friday, November 3rd. BMO Capital Markets assumed coverage on shares of Mednax in a research note on Monday, October 16th. They issued a “market perform” rating and a $46.00 price objective for the company. Finally, Robert W. Baird boosted their price objective on shares of Mednax from $47.00 to $48.00 and gave the stock a “neutral” rating in a research note on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $53.22.

Large investors have recently added to or reduced their stakes in the stock. Pacer Advisors Inc. raised its stake in Mednax by 8.1% during the 2nd quarter. Pacer Advisors Inc. now owns 1,940 shares of the company’s stock valued at $117,000 after purchasing an additional 145 shares during the last quarter. Commonwealth Bank of Australia increased its holdings in Mednax by 15.3% in the 2nd quarter. Commonwealth Bank of Australia now owns 2,205 shares of the company’s stock valued at $132,000 after buying an additional 293 shares during the period. Fuller & Thaler Asset Management Inc. bought a new stake in Mednax in the 3rd quarter valued at $103,000. Daiwa Securities Group Inc. increased its holdings in Mednax by 20.0% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,000 shares of the company’s stock valued at $181,000 after buying an additional 500 shares during the period. Finally, Meiji Yasuda Asset Management Co Ltd. bought a new stake in Mednax in the 2nd quarter valued at $217,000. Hedge funds and other institutional investors own 98.48% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Mednax, Inc (MD) Insider John C. Pepia Sells 3,000 Shares” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/12/12/mednax-inc-md-insider-john-c-pepia-sells-3000-shares.html.

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Insider Buying and Selling by Quarter for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax and related companies with MarketBeat.com's FREE daily email newsletter.